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Background: The International Metastatic Renal Cell Carcinoma Database
Consortium (IMDC) model has been validated for patients with mRCC in the 2nd line
TT setting. This model does not consider time from first to second line therapy, tumor
shrinkage during first line and tumor burden before second-line. We sought to
investigate these factors in addition to IMDC ones.
Methods: Data from patients (pts) treated with TT between January 2005-December
2013 in prospective clinical trials for mRCC were collected from the Gustave Roussy
database. All pts who received 2nd-line TT and had available information from 1st line
were nalyzed. Data collected included known IMDC prognostic factors (anemia,
hypercalcemia, thrombocytosis, neutrophilia, Karnofsky performance status <80, time
from diagnosis to treatment <1year) as well as tumor burden (TB), tumor shrinkage
(TS), time from first to second line, occurrence of new metastatic sites, number of
metastatic sites at second line and histology. Variables with a significant association
with overall survival from the start of second line (OS) were estimated by proportional
hazard regression and a backward stepwise multivariable analysis identified the
independent prognostic factors.
Results: From the initial cohort of 316 pts, 222 pts met inclusion criteria and were
included in the final analysis. 2nd line treatment was everolimus (27%), sunitinib
(24%), sorafenib (22%), axitinib (8%) and other (19%). The median follow-up was 49.4
[range: 2.3 to 97.1] months (mos) and the median OS was 16.8 [95%CI = 12.6, 21.7]
mos (79.3% of deaths). By IMDC criteria, mOS was 21•3 mos (95% CI 7.5–49.5) in the
good risk group (n = 22), 21•7 mos (15.1–24.9) in the intermediate risk group
(n = 142), and 9•3 mos (5.2–12.4) in the poor risk group (n = 58). In univariate
analysis, all adverse prognostic factors previously identified by IMDC, except
hypercalcemia, TB greater than 9•5 cm, TS greater than 30% and occurrence of new
metastatic site were associated with shorter survival. In multivariable analysis, only TS
greater than 30% was an independent prognostic factor (p: 0.0004), among new
potential prognostic factors.
Conclusion: TS during 1st line is an independent prognostic factor for outcome of
mRCC in second line. A new prognostic model considering components of the IMDC
model with the addition of TS will be presented during the meeting.
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